Arkansas wine
Overview of Aplaviroc, an investigational drug
| Arkansas wine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Aplaviroc is an investigational drug that was developed as a potential treatment for HIV/AIDS. It belongs to a class of drugs known as CCR5 receptor antagonists, which are designed to block the CCR5 receptor on the surface of T cells, preventing the HIV virus from entering these cells and replicating.
Mechanism of Action[edit | edit source]
Aplaviroc functions by selectively binding to the CCR5 receptor, a co-receptor that HIV uses to enter CD4+ T cells. By blocking this receptor, aplaviroc prevents the virus from attaching to and entering the host cells, thereby inhibiting its replication cycle. This mechanism is similar to other CCR5 antagonists, such as maraviroc, which are used in the treatment of HIV.
Development and Clinical Trials[edit | edit source]
Aplaviroc was developed by GlaxoSmithKline and underwent several phases of clinical trials. During these trials, the drug was evaluated for its efficacy in reducing viral load in patients with HIV, as well as its safety and tolerability. However, the development of aplaviroc was halted due to concerns about liver toxicity observed in some patients during the trials.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of aplaviroc includes its absorption, distribution, metabolism, and excretion. Aplaviroc is administered orally and is absorbed into the bloodstream, where it exerts its effects on the CCR5 receptor. The drug is metabolized primarily in the liver and excreted through the kidneys.
Potential Side Effects[edit | edit source]
While aplaviroc showed promise in early trials, its development was discontinued due to adverse effects, particularly hepatotoxicity. Other potential side effects observed in clinical trials included gastrointestinal disturbances, headache, and dizziness. The risk of liver damage was a significant concern, leading to the cessation of further development.
Current Status[edit | edit source]
As of now, aplaviroc is not approved for use in any country, and its development has been discontinued. Research into CCR5 antagonists continues, with other drugs in this class being used in clinical practice.
Related Pages[edit | edit source]
Gallery[edit | edit source]
Chemical structure of Aplaviroc
Map of Arkansas
Arkansas Quality Wine Competition
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
